Meeting
2021 Genitourinary Cancers Symposium
Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).
Authors
Alex Chehrazi-Raffle
City of Hope National Medical Center, Duarte, CA
Alex Chehrazi-Raffle , Luis A Meza , Marice Alcantara , Nicholas Salgia , Nazli Dizman , Paulo Gustavo Bergerot , Joann Hsu , Marcin Kortylewski , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 352)
DOI
10.1200/JCO.2021.39.6_suppl.352
Abstract #
352
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.
First Author: Sumanta Kumar Pal
Poster
2022 ASCO Annual Meeting
A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
First Author: Luis A Meza
Poster
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
First Author: Jeffrey Graham
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells